Clinical phase Alzheimer’s disease drugs 2023, by sponsor
As of January 1, 2023, half of all Alzheimer’s disease drugs in clinical trial phases 1, 2, and 3 combined worldwide were sponsored by the biopharma industry, while around 28 percent were sponsored by academic medical centers. This statistic illustrates the trial sponsors of Alzheimer’s disease drugs in development worldwide, by sponsor.